Floatz logo

Tucidinostat

Double-expressor Lymphoma

Ruijin HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Double-expressor Lymphoma cohort.

Asset / SponsorPhaseRating
Epirubicin
Zhejiang Cancer Hospital
Phase 2CCC
VINDESINE
Zhejiang Cancer Hospital
Phase 2CCC

Same molecule, other indications

Tucidinostat is also rated in:

extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →